Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.

In 30 seconds

The multicenter randomized RuxoBEAT trial compared first-line ruxolitinib (RUX) with best available therapy (BAT) in patients with polycythemia vera. At month 6, the primary endpoint—clinico-hematologic complete response—was not achieved, with rates of 2.3% vs. 2.9% (p = 1.000) for RUX and BAT, respectively. Secondary and exploratory analyses favored RUX for hematocrit, splenomegaly, pruritus, and fatigue, while BAT was more effective at reducing platelet counts. Treatment time and duration favored RUX over the 24-month study period; no new safety signals were reported.

Key findings

• Month-6 complete response rates were 2.3% with RUX and 2.9% with BAT (p = 1.000); the primary endpoint was not met.
• RUX was significantly more effective for hematocrit, splenomegaly, patient-reported pruritus, and fatigue, but less effective for platelet-count reduction.
• Time on treatment (p < 0.001) and duration of treatment (p = 0.022) favored RUX during the 24-month study period.
• JAK2V617F variant allele frequency decreased significantly from baseline in both groups at 6 months; no new safety signals were observed.

Why it matters

The trial distinguishes complete response from other disease-control outcomes: first-line RUX did not improve the primary response rate over BAT, yet secondary measures suggested benefits in several clinically relevant disease features and symptoms. These results help frame the potential trade-offs of first-line RUX, including its comparatively weaker effect on platelet counts, without establishing superiority on the primary endpoint.

What to keep in mind

The primary endpoint was not met, and the reported advantages for RUX were in secondary and exploratory outcomes. Crossover from BAT to RUX was permitted after 6 months, which may complicate comparisons over the 24-month study period.